Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Executioner enzyme may short circuit second form of cell death

An enzyme viewed as an executioner, because it can push cells to commit suicide, may actually short circuit a second form of cell death, researchers at Emory University School of Medicine have discovered.

4 Mar 2011

Advion to establish new laboratory at Purdue Research Park near Indianapolis

Advion BioServices Inc., a provider of contract bioanalytical research services, announced that it will establish a laboratory here, creating 49 immediate jobs and up to 66 jobs by 2015.

From Advion 2 Mar 2011

HP announces innovative drug research application for its inkjet technology

HP today announced an innovative drug research application for its inkjet technology that enables pharmaceutical companies to more efficiently develop better drugs through vastly more precise dispensing of dosages.

1 Mar 2011

Daiichi Sankyo enters merger agreement to acquire Plexxikon

Plexxikon Inc. today announced it has entered into a merger agreement with Daiichi Sankyo Company, Limited, a Japan-based global pharmaceutical company.

28 Feb 2011

Janssen-Cilag, NovAlix enter research services agreement for chemistry to support drug discovery efforts

NovAlix today announces that it has entered into a multi-year research services agreement for chemistry with Janssen-Cilag, France, to support its drug discovery efforts.

28 Feb 2011

Selcia completes drug discovery project with ExonHit Therapeutics using fragment screening technology

Selcia Ltd today announced the successful completion of a drug discovery project with ExonHit Therapeutics SA, using Selcia's fragment screening technology. Novel and weak affinity hits were identified from Selcia's Fragment Library, using their proprietary CEfrag technique.

28 Feb 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

Vertex Pharmaceuticals Incorporated today announced positive results from the Phase 3 STRIVE study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

24 Feb 2011

Covance Genomics Lab, Ingenuity enter research collaboration for NGS data analysis

Ingenuity Systems, a leading provider of information and analytics solutions for life science researchers, today announced a research collaboration with Covance Genomics Laboratory for next-generation sequencing data analysis.

24 Feb 2011

Trevena commences TRV120027 Phase 2a trial in patients with acute heart failure

Trevena Inc., the leader in G-protein coupled receptor biased ligand drug discovery, today announced the initiation of a Phase 2a clinical trial with its lead program, TRV120027, a beta-arrestin biased angiotensin II type 1 receptor ligand, the first biased ligand designed to treat patients with acute heart failure.

23 Feb 2011

GIBH, Saint Louis University form global research partnership to combat malaria

The Center for World Health & Medicine at Saint Louis University and China's Guangzhou Institutes of Biomedicine and Health are forming a global research partnership that initially will focus on new treatments for malaria.

19 Feb 2011

Merck Canada announces $6.8 million investment in AmorChem for biopharmaceutical research

Merck Canada announced today a $6.8 million investment in AmorChem, a Quebec life sciences venture capital fund. This is the latest investment made by Merck following a commitment made in 2010 to invest an incremental $100 million over five years in biopharmaceutical research and development in Quebec.

19 Feb 2011

ACEA Biosciences receives new U. S. Patent for chemical compound screening

ACEA Biosciences, a pioneer in the development of high-performance microelectronic systems for cell-based assays, diagnostics, and pharmaceutical research, is pleased to report the issuance of a new U. S. Patent for chemical compound screening, with important applications in the development of new pharmaceutical products.

17 Feb 2011

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

Amicus Therapeutics today announced that additional positive data from the ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease will be presented at the Lysosomal Disease Network WORLD Symposium in Las Vegas, Nevada, February 16-18th, 2011.

17 Feb 2011

GAVI chair calls for greater reductions in vaccine prices for developing countries

On Monday, the same day the GAVI Alliance helped oversee the roll out of a routine pneumococcal vaccine in Kenya, GAVI chairman Dagfinn Hoybraten highlighted the need for greater reductions in vaccine prices in developing countries during an interview with Reuters, the news service reports. The piece examines the funding mechanism in place to finance the pneumococcal vaccines, known as Advance Market Commitment (AMC), as well as the budget shortfall facing the group (Kelland, 2/14).

16 Feb 2011

Researchers use computers to capture chemical signal structure that triggers metastatic cancer

In cancer and other pathological diseases, researchers are discovering that packaging is important: specifically, how DNA - about two meters long when unwound and stretched - coils up and compacts neatly inside the nucleus of a cell.

15 Feb 2011

Public-sector research has had an immediate effect on improving public health: Study

AUTM President Ashley Stevens, D. Phil. (Oxon), CLP is the lead author of The Role of Public Sector Research in the Discovery of Drugs and Vaccines, a paper published in the Feb. 10 issue of The New England Journal of Medicine.

14 Feb 2011

BioCentury features ImmunGene's interferon payload technology and cancer antibodies

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today that a profile of the company and its interferon payload technology platform and drug discovery pipeline is featured in the February 7 issue of BioCentury, one of the most widely read publications in the pharma and biotech industries.

14 Feb 2011

CX3CL1 signaling chemical can offer better understanding of Parkinson's disease

Targeting the neuroinflammatory causes of Parkinson's disease with a naturally present brain chemical signal could offer a better understanding of the clinical mechanisms of the disease and open a future therapeutic window, reports a team of researchers from the University of South Florida Department Neurosurgery and Brain Repair and the James A. Haley Veterans' Administration Hospital, Tampa.

14 Feb 2011

Scientists produce SR-3306 compound to protect brain cells from Parkinson's disease

Scientists from the Florida campus of The Scripps Research Institute have produced the first known compound to show significant effectiveness in protecting brain cells directly affected by Parkinson's disease, a progressive and fatal neurodegenerative disorder.

13 Feb 2011

Drug Discovery News and Research

Further Reading

Executioner enzyme may short circuit second form of cell death

Advion to establish new laboratory at Purdue Research Park near Indianapolis

HP announces innovative drug research application for its inkjet technology

Daiichi Sankyo enters merger agreement to acquire Plexxikon

Janssen-Cilag, NovAlix enter research services agreement for chemistry to support drug discovery efforts

Selcia completes drug discovery project with ExonHit Therapeutics using fragment screening technology

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

Covance Genomics Lab, Ingenuity enter research collaboration for NGS data analysis

Trevena commences TRV120027 Phase 2a trial in patients with acute heart failure

GIBH, Saint Louis University form global research partnership to combat malaria

Merck Canada announces $6.8 million investment in AmorChem for biopharmaceutical research

ACEA Biosciences receives new U. S. Patent for chemical compound screening

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

GAVI chair calls for greater reductions in vaccine prices for developing countries

Researchers use computers to capture chemical signal structure that triggers metastatic cancer

Public-sector research has had an immediate effect on improving public health: Study

BioCentury features ImmunGene's interferon payload technology and cancer antibodies

CX3CL1 signaling chemical can offer better understanding of Parkinson's disease

Scientists produce SR-3306 compound to protect brain cells from Parkinson's disease

Drug Discovery - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News